Show simple item record

dc.contributor.authorDakin, Hen_US
dc.contributor.authorDevlin, Nen_US
dc.contributor.authorFeng, Yen_US
dc.contributor.authorRice, Nen_US
dc.contributor.authorO'Neill, Pen_US
dc.contributor.authorParkin, Den_US
dc.date.accessioned2019-06-11T10:00:55Z
dc.date.available2014-06-20en_US
dc.date.issued2015-10en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/57924
dc.description.abstractThe National Institute for Health and Care Excellence (NICE) emphasises that cost-effectiveness is not the only consideration in health technology appraisal and is increasingly explicit about other factors considered relevant but not the weight attached to each. The objective of this study is to investigate the influence of cost-effectiveness and other factors on NICE decisions and whether NICE's decision-making has changed over time. We model NICE's decisions as binary choices for or against a health care technology in a specific patient group. Independent variables comprised of the following: clinical and economic evidence; characteristics of patients, disease or treatment; and contextual factors potentially affecting decision-making. Data on all NICE decisions published by December 2011 were obtained from HTAinSite [www.htainsite.com]. Cost-effectiveness alone correctly predicted 82% of decisions; few other variables were significant and alternative model specifications had similar performance. There was no evidence that the threshold has changed significantly over time. The model with highest prediction accuracy suggested that technologies costing £40 000 per quality-adjusted life-year (QALY) have a 50% chance of NICE rejection (75% at £52 000/QALY; 25% at £27 000/QALY). Past NICE decisions appear to have been based on a higher threshold than £20 000-£30 000/QALY. However, this may reflect consideration of other factors that cannot be easily quantified. © 2014 The Authors. Health Economics published by John Wiley & Sons Ltd.en_US
dc.description.sponsorshipconsortium of British Pharmaceutical companies: Amgen, AstraZeneca, BMS, Celgene UK & Ireland, GSK, Lilly UK, Merck, Merck Serono, Pfizer, Sanofi Aventis, Schering Plough, Takeda UK, and Wyethen_US
dc.format.extent1256 - 1271en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofHealth Econen_US
dc.rightsCreative Commons Attribution License*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0*
dc.subjectNational Institute for Health and Care Excellence (NICE)en_US
dc.subjectcost-effectivenessen_US
dc.subjecthealth technology assessmenten_US
dc.subjectimplicit weightsen_US
dc.subjectlogistic regressionen_US
dc.titleThe Influence of Cost-Effectiveness and Other Factors on Nice Decisions.en_US
dc.typeArticle
dc.rights.holder© 2014 The Authors
dc.identifier.doi10.1002/hec.3086en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/25251336en_US
pubs.issue10en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume24en_US
dcterms.dateAccepted2014-06-20en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution License
Except where otherwise noted, this item's license is described as Creative Commons Attribution License